Introduction
Long-term pharmacotherapy is paramount to the successful management of inflammatory arthritis (IA), as patients rely on medications to relieve symptoms, perform daily life activities and prevent irreversible joint and organ damage. 1 Systematic reviews synthesizing adherence rates as low as 10% in gout, 2 25% in systemic lupus erythematosus (SLE) 3 and 30% in rheumatoid arthritis (RA) 4 are alarming, given the
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rai et al association between non-adherence and adverse outcomes, including increased health care utilization, 5, 6 costs 7-9 and decreased ability to work. 10 Given this substantial burden of non-adherence among patients with IA, there is an urgent need for work in designing and evaluating interventions that promote and support treatment adherence. However, to date, such research has been disappointing, with less than half of published interventions reporting a significant impact on medication adherence or clinical outcomes. 11 These data support the importance of soliciting patient input to inform the development of successful adherence strategies and interventions.
Patient-oriented research, defined as meaningful and active collaboration in priority setting, conducting and translating research, 12 may provide an ideal opportunity to address the burden of non-adherence in IA. To illuminate practical strategies and solutions that may be operationalized into effective adherence interventions through a patient-centered lens, we conducted a patient-oriented qualitative study in partnership with a leading national arthritis patient group based in British Columbia (BC), Canada. Our objective was to explore IA patients' perspectives on tools and strategies to support chronic medication use using an interactive focus group activity.
Methods
Patient partnership
We partnered with the Arthritis Patient Advisory Board (APAB) of Arthritis Research Canada, a leading national consumer group of individuals living with IA who regularly collaborate in arthritis research. 13 As we describe in further detail below, APAB members were engaged throughout the research process, including grant preparation (with one member appointed as a co-investigator on the study team), participant recruitment, focus group activity design and refinement, data analysis and interpretation and manuscript writing.
Study sample
Eligible participants were those who met the following criteria: 1) rheumatologist-confirmed diagnosis of IA, 2) 19 years of age or older, 3) currently taking medication (eg, disease modifying anti-rheumatic drugs [DMARD] ) for their IA and 4) able to communicate in English. Participants were recruited from rheumatology clinics in the lower mainland of BC. APAB supported study recruitment through their various social media channels, including their quarterly electronic newsletter, members' Twitter feeds and word-of-mouth advertising. Although we originally intended to include only patients with RA, APAB members recommended including a broader range of inflammatory arthritis, given that many conditions share similar treatments, and to ensure capture of rarer conditions that were less represented in prior qualitative research of medication use. As such, we purposively sampled participants on age, sex, type and duration of IA diagnosis and IA medication(s) prescribed to obtain diverse perspectives and experiences.
Study design and methodology
We used a qualitative approach for data gathering, specifically focus group methodology, as processes and interactions within focus groups more readily facilitate people's exploration and clarification of views than oneon-one interviews and can enhance the depth and breadth of the information obtained.
14, 15 We used a relatively novel technique of incorporating a group activity to focus the attention of the group on the core topic of the study. 16 Specifically, a trained facilitator asked participants to describe or design at least one strategy and/or tool (whether hypothetical or currently available) that would support their medication use on color-coded labels and corresponding activity sheets provided. Participants were then invited to share their strategies/tools with the group and the facilitator used open-ended questions to promote discussion. To allow sufficient time for the activity and subsequent discussion, focus groups were formed with four to six participants. Each focus group interaction lasted approximately two hours and was audio recorded and transcribed verbatim for analysis. At least one study team member attended all focus group interactions as an observer, noting elements of participants' actions and interactions. APAB inputs for the focus group design included providing feedback on the topic guide to ensure the use of appropriate and accessible language that would effectively engage participants; furthermore, we conducted a pilot focus group interaction with six APAB members to identify areas for improvement in execution of the group activity. The uses of color-coded labels and activity sheets were a direct result of this pilot focus group with APAB, as we had originally proposed the uses of poster boards and cards attached with velcro, which were found cumbersome and potentially challenging for the target patient population. 
Data analysis
Analysis of the focus group data was guided by thematic analysis informed by aspects of grounded theory 17 and used an iterative, constant comparative approach. 18 The first step in this approach was open coding, whereby each line of the transcript was ascribed individual codes that represented its main concept or phenomenon. This was an iterative process, since information from previous decisions helped to inform subsequent ones and vice versa. Constant comparison helped to identify patterns and similarities between data from different transcripts and notes were made to help inform subsequent steps in the analysis. The second step was axial coding, where codes were condensed and sorted; similar phenomena were grouped together and relationships between codes were explored and mapped. Finally, selective coding resulted in a final list of five higher-level themes and associated categories that captured the main ideas discussed by participants in relation to their experiences with the disease and medication use. This list was reviewed in relation to existing literature and theories on this topic and additional themes or categories were added. All six transcripts were subsequently reviewed and recoded according to these themes. Furthermore, APAB members provided input on study results during interim and final presentations on elucidated themes.
Results
We held six focus group interactions with a total of 27 participants, including 17 women and 10 men. As shown in Table 1 , our sampling strategy achieved a broad representation of diagnoses, including RA, psoriatic arthritis (PsA) and ankylosing spondylitis (AS), as well as comparatively underrepresented conditions in this research area (eg, Sjögren's syndrome and granulomatosis with polyangiitis). Nine participants had been living with IA for 5 years or less and 18 participants for over 5 years. Table 1 also shows current IA medications taken by participants; methotrexate was the most common medication taken by participants (n=15), either alone or in combination with another DMARD. A total of 13 participants were taking biologic therapy.
Five themes emerged from the analyses. The first two themes of 1) adapting to life with IA and 2) the complexities and dynamic nature of taking medications described the interrelated experiences of living with and taking medications for IA, with illustrative quotes for each theme and category provided in Table 2 . Then three overlapping and interlocking themes of 3) developing lifestyle strategies for "…I've had to adjust a lot and it seems to be a continual process of adjusting to your new normal. And you've had to basically grieve the loss of your old self and get over yourself." (RA, SjS, cyclosporine, adalimumab) 3. Accepting the disease "And I too being diagnosed so young, I kept thinking I'm going to get past this. And I bet you it took me 25 years before I finally gripped that I've got this for life and that I'm going to have bad days and good days. So that was the real turning point for me where I finally started to be more accepting of it." (RA, methotrexate, golimumab) 4. experiencing personal, social and career impacts "…and even the social implications because of the fact that a lot of times it's episodic or unpredictable. You can get up one day and you're feeling fine and the next day could be, like, okay I can't get up. And so even the implications for working or implications for social. You make plans with people and you have to cancel or postpone or something like that. Where before… So it does impact your life. It all impacts your feelings because it's emotions and you do go through a lot of emotions." (RA, SjS, cyclosporine, adalimumab) Theme 2: Complexities and dynamic nature of taking medications 1. Taking medications Managing multiple medications "…we started this whole regime of three or four drugs and the side effects on all of those." (rA, methotrexate, rituximab) Using needles "I'm going to have to psych myself up to do it. Even though I'm good with the needle and it doesn't hurt at all, it's a real psych up to do it. I always end up putting it all to the last thing at night." (RA, hydroxychloroquine, methotrexate, sulfasalazine) Frequency of taking medications "…I'd like to tell [drug companies] to make some pills that are more sort of like a methotrexate that you take once a week rather than every day or whatever. Make it last longer but somehow design it and such so that it's slow release." (RA, methotrexate) 2. 
information needs
How to take medication "You could eat the wrong things in combinations with some medications if you don't know that you're not supposed to eat or drink, you know, like alcohol or whatever." (RA, SjS, cyclosporine, adalimumab) Side effects "Explain to me why it says I can possibly get cancer from this drug. Because I'm sure it's a reason like someone, I mean we've all googled it. Someone was taking the drug while they got cancer. But when I read it on my box of Enbrel, I'm thinking, 'oh dear this thing is going to give me cancer?' All of that information would be very helpful. I'd be less frightened to take Enbrel every week if I really knew why it said [that]…" (AS, etanercept) How the medication works/Importance of the medication "The knowledge is basically why I am taking this medication for. So that I understand that basically what it's going to do to my body. Is it going to work? And just basically educating myself from that drug and understanding how it's going to work in my body." (PsA, etanercept) Information from other patients "I guess there would have to be an initiative to, I guess, people like us who write down their experiences and it is verified by their doctors that this is their experience." (RA, hydroxychloroquine) Information for family members and caregivers "….But you go through this personal trauma and when your family is not as informed as you are, you know…" (RA, gold) Getting trusted information "And one thing for me that's really important is knowing that the information is trusted. And I know sometimes… I've gone to the Mayo Clinic or I've gone to Live Strong or some different sites like that. And comments are helpful when, you know, sometimes you read the comments and sometimes they're helpful and sometimes they're not. And what would be great would be if there were sort of doctor-approved comments or doctor-approved experiences." (RA, hydroxychloroquine) "…like it has to come from a reliable source on the Internet and not everybody knows what reliable sources are." (RA, SjS, cyclosporine, adalimumab) 3. Means of receiving information Arthritis group classes "Not everybody will do it [medication use] the same way. But I think having somebody here [at the arthritis centre] like one of the resource people emphasizing the tools because I don't remember anyone talking to me about how I will establish good habit and regimen and how to maintain it. i don't remember that happening in a conversation ever. So if that could all be combined in one, that would be so incredibly helpful… If it was linked [to websites] where you can actually look at this is the side effect and these are the drug interactions… almost like an information thing. That would be a lot more helpful then having to go to all these things individually." (AS, golimumab) "I would like an Apple application. There are a couple out there and all they really do is remind you or they remind the person that you assign if you don't take your medication. But for me sometimes I push it back earlier or later. So I like the reminder of 'hey take your medication', and then actually ask, 'oh did you take your medication or did you take it the next day? And why did you change it?"' (PsA, methotrexate, adalimumab) "The other thing would be to do a non-techy app thing, which would be to develop a wheel that's divided into seven pieces of pie, so to speak, which has each day of the week on it and with only day being revealed and you turn it each day. And in there it says exactly what you're supposed to be taking that day." (RA, hydroxychloroquine) reasons for the onset of their condition -"I mean why did this happen to me? Is it genetic? Is it something that I ate?" (RA, methotrexate). Many also described the adjustment -both initially from being a healthy individual to having a diagnosis and the associated loss of identity, as well as with respect to long-term acceptance of living with a chronic condition. Through these, participants touched on "…big restrictions…" (RA, gold) imposed on them by their diseases, with impacts on families: "I've got a young kid and another one coming. So it's tough for me to do things at home with them" (AS, etanercept), on friendships: "…I think I've lost friends over it…" (RA, gold) and on careers: "[Doctor] had said a while ago to apply for disability and I didn't want to. I wanted to keep working" (AS, adult-onset Still's disease, methotrexate, sulfasalazine, etanercept).
Theme 2: Complexities and dynamic nature of taking medications for inflammatory arthritis
Intertwined with participants' experiences of their IA diagnoses were their experiences with medications, which were summed across six categories as complex and dynamic: "Every single drug they tried me on I have either a physical reaction or worse. So it's been a very long frustrating journey" (RA, gold). Four categories -1) taking medications, 2) trying different medications, 3) being able to afford medications/accessing expensive medications and 4) experiencing unwanted effects of medications -capture the challenges experienced by participants in taking medications for their IA. For example, the first category included issues on managing multiple medications and administering medications, particularly the use of needles with the sentiment "…I hate needles…" (AS, hydroxychloroquine, golimumab) echoed across focus groups. Being able to afford medications or the process of accessing medications (particularly biologics) was also identified as a challenge, as well as experiencing unwanted side effects of medications such as injection site inflammation, allergic reactions, nausea, infections and complications associated with other organs (eg, neurological complications) and worrying about longterm effects of chronic medication use. The fifth category, not taking medications, captures both intentional -"…I was very anti-drug. So when I was diagnosed, I was actually given a prescription for methotrexate, which I did not use" (RA, SjS, cyclosporine, adalimumab) -and non-intentional -"Because if I'm out with friends or if I'm really tired after a long week, I will forget" (RA, hydroxychloroquine, methotrexate, tocilizumab) reasons why participants did not take IA medications. Finally, despite challenges, we also identified a sixth category of feeling better with medications and how medications had positively impacted their IA: "It's like a cloud has been lifted and I can function" (PsA, methotrexate, adalimumab).
Theme 3: Developing lifestyle strategies for medication use
The third theme captures lifestyle strategies, both already implemented and suggested, by participants that support medication use. Consistent across focus groups was making a routine of taking medication, for example, at the same time each day or each week, or combining it with other daily activities that can serve as a reminder: "make that medicine so much part of your life that you do not think about it. It's like eating." (RA, methotrexate, rituximab). Facilitating the development of routines was planning ahead, for example, injecting methotrexate on weekends and having medications on hand at all times, as well as having physical reminders and prompts, such as placing medications with routine household items (eg, beside a toothbrush). Organizational tools such as blister packs obtained from pharmacies as well as pill cases were also found to be useful, along with calendars. In the fourth theme, participants discussed various aspects of becoming informed about IA medications across three categories of: 1) receiving information at the time of diagnosis, 2) information needs and 3) means of receiving information. Participants touched on the importance of receiving sufficient information about medication at the time of IA diagnosis which some felt was lacking when they were diagnosed. Various information needs were captured in the second category including how to take the medication, side effects, as well as how the medication works and placing an emphasis on its importance: "I think the big one is impressing on a lot of people how important it is to take your medication and that missing a dose can be pretty disastrous for some people" (PsA, etanercept). Hearing about other patients' experiences of living with IA and using prescribed medications was viewed mostly positively: "…and then from people who experience it. Just say, 'Hey this is my experience and, you know, how it could progress. You can do this" (AS, hydroxychloroquine, golimumab). In addition to their own information needs, some felt that education of family members would also be helpful:
And if I could add I think the education of your spouse or caregiver to know that having the medications needed to be done pretty well at the same time is going to make it easier for you to be able to make the commitments for social activities and things and for that to be part of the education process. It helps to just keep the whole thing on course, right? (RA, methotrexate, sulfasalazine).
Aside from the type of information, participants also emphasized the importance of being able to recognize whether information was credible or trustworthy; this was particularly important for information collected from the Internet. The final category identified means of receiving information about medications, including group classes, written resources and in particular, digital technologies.
Theme 5: receiving support
This theme describes a number of means by which patients receive support, including functional and emotional, from individuals such as health care providers and family members as well as other tangible supports. The first category captures the importance of education from participants' health care providers, including rheumatologists and nurses as well as pharmacists. However, participants also noted challenges with health encounters, particularly the need for more time, especially when explaining their conditions and medications. The second category captures the importance of support from family, whether it is reminding participants to take their medications or helping administer medications. The third category captures the role of digital technologies in supporting medication use. Participants identified two main technologies -the Internet and smartphones -that they used, as well as anticipate other patients with IA using. Health apps were also discussed and within this subcategory participants described desired features and functions of medication taking apps, such as setting more detailed reminders for multiple medications (eg, including dosage information), cataloging information about missed or altered doses, recording side effects and synchronizing with the pharmacy and insurance company. Finally, within the fourth category, some participants also noted other supports, including patient support programs provided by drug companies for the use of biologics:
I was set up with, well not a nurse but the drug company themselves. And they did everything for me from the spe- 
relationship between themes
From our analyses, there are two essential considerations for adherence -information (as captured in Theme 4) and support (as captured in Theme 5) and we outline a framework for patient-oriented adherence interventions for IA. In the framework shown in Figure 1 , actionable targets for adherence interventions for IA represent potential areas for designing patient-oriented adherence interventions. These areas may be in the form of receiving support as captured by Theme 5. For example, an adherence intervention may be designed to facilitate encounters with health care team members to optimize patient support. Another target area for an adherence intervention for IA is through means of receiving support as captured by Theme 4, category 3. With this, an adherence intervention may be designed around arthritis group classes, written resources, or digital technologies as means to deliver information. Outside of the actionable targets but also key to this framework is Theme 4's category 1 of "information needs" which represents inputs for these actionable targets in terms of patient-identified knowledge gaps that could be readily addressed by the interventions.
Discussion
We conducted a patient-oriented qualitative study using an interactive focus group activity to better understand IA patients' perspectives on and experiences with chronic Aside from confirming recommendations, including those from the European League Against Rheumatism on patient education for people with IA as priority care, 19 our finding on the importance of becoming informed about medications supports results from our prior systematic review of medication adherence interventions in IA, that those shown to have an impact on adherence outcomes included an educational component.
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Perhaps more valuable, the current qualitative study identifies tangible areas for education development drawn directly from patients with IA such as when information should be delivered (ie, at the time of diagnosis) and what information is desired. With respect to the latter, our findings suggest that educational tools that effectively present how to take medications, how medications work, including potential benefits in addition to the risks may be helpful to individuals with IA. Furthermore, patients with IA emphasized the need for information to be drawn from the experiences of other patients, which has been echoed in studies in RA 20 and SLE 21 populations. For example, utilizing other patients' experiences may help to alleviate apprehensions about medication side effects, as identified in prior studies. 22, 23 Lastly, patient preferences for information delivery extended beyond the typical health care setting to patient groups, written resources and digital technologies, thereby highlighting future avenues for intervention development. Such informational tools and resources may be further bolstered by behavioral strategies that support daily medication use. Indeed, participants in the current study described specific strategies used to overcome the daily logistical challenges encountered with long-term medication use.
Study participants with IA indicated multiple opportunities to optimize medication adherence through functional and/or emotional support, namely by means of health care professionals, family and digital technologies. Indeed, the important role of health care providers in supporting medication use has been shown in recent qualitative syntheses among patients with RA, 20 systemic autoimmune rheumatic diseases, 24 and gout. 25 Importantly, our study adds a collective perspective from IA patients, including those living with less common forms of IA, on some of the challenges with health care providers, including the need for more time during encounters as well as improved communication, particularly when multiple providers are involved in a patient's care. Also, similar to prior qualitative inquiry in IA, 22 ,23 our focus groups articulated how family can provide reminders and assist with administering injections, all while having a deeper insight into the personal experiences and needs of the individual with IA. Aside from identifying the supporting role of family members, participants in our study also identified the need for information to be delivered to family members themselves.
In terms of other tangible supports, study participants identified the role of digital technologies which have indeed gained traction in supporting care in rheumatology, with implications for medication use. 26 With health apps forming a sub-category within this theme, participants identified a number of desired features such as the ability to organize medications or serve as a means to communicate a patient's medication taking to their rheumatologist or pharmacist. Indeed, the ubiquitous and accessible nature of digital technologies makes for potential adherence support tools. However, there remains need for work in this area. We conducted a scoping review and quality assessment and identified 704 smartphone medication adherence apps in Apple and Android platforms and noted that the primary function of the majority of apps was sending a reminder or alert to users to take their medication. 27 Apps specific to rheumatic diseases, such as SLE 28 and RA, 29 however focus on monitoring disease activity rather than medication use. As such, subsequent directions to optimize medication adherence may include building apps specific to IA that incorporate patient preferences such as dynamic follow-up after the initial dose reminder, access to reliable drug information and synchronization with pharmacies and insurance companies.
Strengths and limitations
The strengths of our study deserve comment. Unique to our study is the patient-oriented approach used to explore medication use among individuals with IA. Engaging APAB, a renowned arthritis patient organization in Canada, throughout the research enriched the execution of this study, including input on the use of patient-friendly language in the topic guide, opportunity to pilot and refine the focus group and embedded activity, as well as providing a "patient lens" to the interpretation and reporting of the findings. Further, strengthening our study is the use of focus groups, as group processes and interactions more readily facilitate participants' exploration and clarification of views and opinions as compared with one-on-one interviews, thereby enhancing the depth and breadth of the information obtained. 14, 15 Next, while the majority of focus group participants were individuals with RA, we were additionally able to recruit individuals with less common forms of IA that have generally been underrepresented in prior qualitative research in this area.
Moreover, our findings across these patient populations suggest largely shared experiences and perspectives on the topic, thereby broadening the applicability of our findings.
Nevertheless, potential limitations of our study also warrant discussion. Participant recruitment primarily took place in the metropolitan city of Vancouver; however, those living in rural communities in BC were also invited to participate through phone or videoconference, thereby broadening the representation of our sample and increasing the generalizability of our findings. Next, those who voluntarily participated in our study may be more likely to use their medications as prescribed and thus might not reflect the perspectives of "non-adherent" individuals. However, this is an inherent limitation of all voluntary research studies and is not limited to the current study.
Conclusion
This patient-oriented qualitative study conducted in the Canadian province of BC has enriched our understanding of the complexities of medication use in IA. Beyond confirming the roles of information and support as facilitators of medication use, we have established a framework that identifies practical and actionable targets for patient-oriented adherence interventions for IA.
Data availability
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